Methodological approach:
Perform Western blot using lysates from SUN1-knockout cell lines (e.g., CRISPR-edited HT1080 cells) alongside wild-type controls. Expect bands at ~90-102 kDa depending on isoform expression .
Combine with immunofluorescence to verify nuclear envelope localization, using co-staining with lamin B1 as a spatial reference .
Validate via siRNA knockdown followed by quantitative PCR to confirm reduced SUN1 mRNA levels correlate with diminished antibody signal .
Live-cell imaging: Transfect SUN1-GFP constructs with KASH5-mCherry to visualize LINC complex dynamics during nucleokinesis .
Biomechanical assays: Use atomic force microscopy to measure nuclear stiffness in SUN1-depleted cells vs. controls .
Viral controls: Include HIV-1-GFP with capsid mutation G208R (resistant to SUN1-mediated restriction) .
Cellular controls:
Binding assays: Use in vitro assembled HIV-1 CA-NC complexes to test direct SUN1-capsid interaction .
γH2AX co-staining: Quantify DNA damage foci in SUN1-depleted cells after ionizing radiation .
Comet assay: Compare DNA migration patterns between wild-type and SUN1-knockout cells .
CHIP-seq: Map SUN1 binding sites near fragile genomic regions using ab124770 for chromatin immunoprecipitation .